KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Subscribe To Our Newsletter & Stay Updated